Members Login
Medical News Feed
EPG Search
Frequent Searches:
Browse Other Languages
Spanish Drug Data (España)
German Drug Data (Deutsch)
Norwegian Drug Data (Norge)
Netherlands Drug Data (Nederlands)
Swedish Drug Data (Sverige)
German Drug Data (Deutsch)
Norwegian Drug Data (Norge)
Netherlands Drug Data (Nederlands)
Swedish Drug Data (Sverige)
YouTube - Featured Content
Want to submit or suggest content for the epgonline.org YouTube Clinical channel?
Contact us here
epgonline.org is not responsible for content on any 3rd party website
Are you a Doctor or Healthcare Professional? Authorise Viewing
Please register to access disease diagnosis, patient management, physician tools.
By viewing the content of this web page you are both confirming your status as a healthcare professional and agreeing to our terms of use.
Change language
Current language database:
United Kingdom
Drug details for : PEDIACEL
| Drug class description : | Vaccines |
| Generic Name : | Diphtheria, tetanus, five component acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate vaccine (adsorbed) |
| Drug description : | Each 0.5 millilitre dose contains: Purified diphtheria toxoid…………not less than 30 international units* (15 Lf) Purified tetanus toxoid…………….not less than 40 international units* (5 Lf) Purified pertussis toxoid (PT)……………………20 micrograms Purified filamentous haemagglutinin (FHA)…….20 micrograms Purified fimbrial agglutinogens 2 and 3 (FIM)…..5 micrograms Purified pertactin (PRN)…………………………...3 micrograms Inactivated type 1 poliovirus (Mahoney)……….40 D antigen units** Inactivated type 2 poliovirus (MEF-1)………….8 D antigen units** Inactivated type 3 poliovirus (Saukett)…………32 D antigen units** Haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate)……………………10 micrograms conjugated to tetanus toxoid (PRP-T)…………..20 micrograms * As lower confidence limit (p=0.95) of activity measured according to the assay described in the European Pharmacopoeia **or equivalent antigenic quantity determined by a suitable immunochemical method. Active components of the vaccine are inactivated with either formaldehyde or glutaraldehyde. Inactivated poliovirus components are produced using the Vero cell line. |
| Presentation : | Suspension for Injectionin a vial Diphtheria, tetanus, five component acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate vaccine (adsorbed). |
| Indications : | PEDIACEL® is indicated for the active immunisation of infants against diphtheria, tetanus, pertussis, poliomyelitis and invasive infections caused by Haemophilus influenzae type b. PEDIACEL® may also be administered as a single dose to children who have previously completed a primary immunisation series with diphtheria, tetanus, pertussis, polio and Hib antigens (See Adverse Reactions), in accordance with the applicable official recommendations. |
| Child Dosage : | Primary Immunisation Series in Infancy The primary immunisation series in infancy may be commenced from two months of age according to applicable official recommendations. A single 0.5 millilitre dose should be given on three separate occasions with at least one month between doses. There are no data regarding the administration of PEDIACEL® for one or two doses and use of different vaccine(s) for other dose(s). Therefore, it is recommended that infants who receive PEDIACEL® for the first dose should also receive this vaccine for the second and third doses of the primary immunisation series. Booster Dose After completion of the primary series, a booster dose of Hib conjugate vaccine should be administered. The timing of this Hib conjugate booster dose should be in accordance with official recommendations. A single 0.5 millilitre dose of PEDIACEL® may be used to provide the Hib booster dose if it is officially recommended to boost responses to all other antigens in the vaccine at the same time. Based on safety and immunogenicity data from clinical studies, PEDIACEL® should preferably be given to children who received this same vaccine in infancy. However, if necessary, PEDIACEL® may be given at this age to children who received other vaccines in infancy. PEDIACEL® should not be administered to children after reaching the fourth birthday. Method of Administration PEDIACEL® should be administered intramuscularly. The recommended injection sites are the anterolateral aspect of the thigh in infants and the deltoid region in older children. |
| Contra Indications : | PEDIACEL® should not be given to children who: -Are known to be hypersensitive to any component of the vaccine (including neomycin, streptomycin and polymyxin B which may be present in trace amounts). -Have had a previous severe local or general reaction to this vaccine or to any other vaccine that contains one or more of the antigenic components. -Have experienced encephalopathy, not due to another identifiable cause, within 7 days of administration of a previous dose of any vaccine containing pertussis antigens (whole cell or acellular). Encephalopathy refers to a severe acute neurological illness with prolonged seizures and/or unconsciousness and/or focal neurological signs. In these circumstances the vaccination course should be continued with vaccines not containing a pertussis component. -Have a fever or acute severe systemic illness. In this case vaccination should be postponed until the child has recovered. Minor infections without fever or systemic upset are not reasons to postpone vaccination. |
| Special Precautions : | As with all vaccines, appropriate facilities and medication such as epinephrine (adrenaline) should be readily available for immediate use in case of anaphylaxis or hypersensitivity following injection. If any of the following events are known to have occurred in temporal relation to a previous dose of a pertussis-containing vaccine, the decision to give further doses of pertussis-containing vaccines should be carefully considered: -Temperature of 40°C within 48 hours, not due to another identifiable cause. -Hypotonic hyporesponsive episode (HHE): a syndrome characterised by acute diminution of sensory awareness or loss of consciousness, accompanied by pallor and muscle hypotonicity. The onset is usually 1-12 hours after vaccination and the episode may last from a few minutes up to 36 hours. Recovery is complete with no persistent sequelae. -Persistent, inconsolable crying lasting more than 3 hours occurring within 48 hours of vaccination. -Convulsions with or without fever occurring within 3 days of vaccination. In children with a progressive, evolving or unstable neurological condition (including seizures), immunisation should be deferred until the condition is corrected or stable. The immunogenicity of the vaccine may be reduced by immunosuppressive treatment or immunodeficiency. It is recommended to postpone vaccination until the end of such treatment or the resolution of disease. Nevertheless, vaccination of subjects with chronic immunodeficiency (such as those with HIV infection or on long-term immunosuppressive therapy) is recommended even though the immunological response may be impaired and the degree of protection may be limited. Intramuscular injections should be given with care in patients with thrombocytopenia or bleeding disorders due to the risk of haemorrhage. The vaccine should be given intramuscularly since subcutaneous administration increases the chances of an injection site reaction. Do not administer by intradermal or intravenous injection. PEDIACEL® does not protect against infectious diseases caused by Haemophilus influenzae other than type b, or against meningitis caused by other organisms. As with any vaccine, immunisation with PEDIACEL® may not protect all recipients from the infections that it is intended to prevent. Applicable official recommendations for childhood immunisations should be consulted before administering this vaccine to children in or after the second year of life since this exact combination of antigens may not be considered appropriate and/or necessary after completion of the infant immunisation series. |
| Interactions : | PEDIACEL® may be administered at the same time as, but as a separate injection to, meningococcal group C conjugate vaccines or hepatitis B vaccines. Injections should be made into separate sites and, preferably, into separate limbs. Antibody responses to the Hib component of PEDIACEL® (PRP conjugated to tetanus toxoid) were lower when a meningococcal group C CRM197 conjugate vaccine was co-administered as a separate injection than when a meningococcal group C tetanus toxoid conjugate vaccine was co-administered as a separate injection at 2, 3 and 4 months of age. The clinical significance of these observations is unknown but the findings relating to meningococcal group C CRM197 conjugate vaccine may have implications for the timing of and need for a Hib conjugate booster dose. The type of meningococcal conjugate vaccine that is co-administered may also affect responses to the diphtheria and tetanus components of PEDIACEL®. Anti-diphtheria responses were higher when a meningococcal group C CRM197 conjugate was co-administered with PEDIACEL® and anti-tetanus responses were higher when a meningococcal group C tetanus toxoid conjugate was co-administered. However, responses to both these antigens were satisfactory regardless of the type of meningococcal group C conjugate that was given. PEDIACEL® did not affect the proportions of infants with meningococcal group C serum bactericidal antibody (SBA) titres of at least 1:8 (measured with rabbit complement) when co-administered with either a CRM197 conjugate or a tetanus toxoid conjugate vaccine. However, the SBA geometric mean titres (GMTs) were numerically lower after co-administration with PEDIACEL® than were seen when these same meningococcal group C conjugate vaccines were co-administered with a whole cell pertussis (as DTwP) vaccine. Also, the SBA GMT when PEDIACEL® was co-administered with a meningococcal group C tetanus toxoid conjugate vaccine was significantly lower than that seen after co-administration with a CRM197 conjugate. However, the clinical significance of the lower SBA GMTs is unknown. There are currently no data on the concomitant use of PEDIACEL® and pneumococcal conjugate vaccine. However, concomitant use may be considered if medically important or in accordance with applicable official recommendations. There are no data on immune responses to hepatitis B vaccines when co-administered with PEDIACEL®. However, there are no safety concerns regarding co-administration. Except for immunosuppressive therapy (See Special Precautions), no significant interaction with other treatments or biological products is anticipated. Pregnancy and lactation As PEDIACEL® is not intended for use in adults, or in children above the age of 4 years, information on the safety of the vaccine when used in pregnancy or lactation is not available. |
| Adverse Reactions : | In controlled clinical studies performed with PEDIACEL®, 71% of 451 infants immunised at 2, 4 and 6 months experienced a reaction (pain, erythema or oedema) at the injection site within the first 24 hours after vaccination. In 16% of infants the reaction was of moderate to severe intensity. Also, 64% of infants experienced a systemic reaction, which was of moderate to severe intensity in 16%. There was a trend for an increased frequency of injection site reactions when a fourth dose of PEDIACEL® was given to 401 children in the second year of life. Pain was reported in 33%, erythema in 23% and oedema in 16% compared to rates of 18%, 11% and 11%, respectively, during the primary series. The frequency of systemic reactions was similar whether PEDIACEL® was administered in infancy or in the second year of life. The reactions observed were as follows: Nervous system disorders Rare (0.01-0.1%): Febrile convulsions. Hypotonic hyporesponsive episodes (HHE) (See Special Precautions). Gastrointestinal disorders Common (1-10%): Anorexia, diarrhoea and vomiting. General disorders and administration site conditions Very common >10%): Pain, erythema and oedema at the injection site. Irritability, malaise, increased crying and fever. Very rare (<0.01%): High fever >40.5°C). Unusual high-pitched or inconsolable crying. Painless circumferential limb swelling following booster doses which resolve spontaneously. In a controlled clinical study of PEDIACEL®, administered concomitantly with meningococcal group C conjugate vaccine, 71% of 121 infants immunised at 2, 3 and 4 months experienced a reaction (pain, erythema or oedema) at the PEDIACEL® injection site within the first seven days after vaccination. Also, 92% of infants experienced a systemic reaction within the first seven days after vaccination. The rates of moderate to severe reactions were similar to those described at 2, 4 and 6 months. Acute allergic reactions have been reported after diphtheria, tetanus and/or pertussis vaccines. Manifestations include dyspnoea, cyanosis, urticaria, angioneurotic oedema, hypotension and, rarely, anaphylaxis. A persistent nodule at the site of vaccination may occur with all adsorbed vaccines, particularly if administered into the superficial layers of the subcutaneous tissue. Rarely aseptic abscesses have been reported. Following administration of vaccines containing Haemophilus influenzae type b conjugated to tetanus toxoid, atypical rashes have sometimes been observed and rarely urticarial eruptions, localised oedema, pruritus and oedematous reactions of the lower limbs. The latter consist of oedema with cyanosis or transient purpura that appears soon after immunisation and resolves rapidly and spontaneously. |
| Manufacturer : | Sanofi Pasteur MSD |
| Drug Availability : | (POM) |
Free registration to access disease diagnosis, patient management, physician tools.
Only registered users have access to the full EPG Online Knowledge Base including drug search tools, interactive disease Knowledge Centres via the EPG Knowledge Library - with clinical and evidence based physician and research tools, MiMedia (build your own clinical media collection with everything from key opinion leader essays to mode of action videos and other multi-media content), the EPG Survey panel, health news updates and much much more.
Already Registered?
Please log-in now using our member login box.
Not a member?
Don't worry, registration is quick and FREE! We welcome all Healthcare professionals, doctors, nurses and medical students.
Register today to have full access to a wealth of drug data, educational and evidence based interactive guides across all major therapeutic areas, disease management, and clinical tools.
As a practicing Healthcare professional, you can also opt-in to join our market research panel – www.epgsurvey.com – and get paid for sharing your expert clinical opinions!
REGISTER today it only takes a minute! and it's FREE
Having problems?
Use our forgotten password facility or email us at: contact@epgonline.org